March 8, 2010 (Miami Beach, Fla.) -- If the drug Enbrel stops working, people with psoriasis have two effective
options, new research suggests.
Although Enbrel works for many people with psoriasis, one new study shows
that the recently approved drug Stelara can help treat moderate to severe
psoriasis if Enbrel fails.
A second study suggests Remicade is effective for people with psoriasis who are
no longer helped by Enbrel.
The findings were presented at the annual meeting of the American Academy of
Dermatology. Both studies were sponsored by Centocor, which makes Stelara and
About 7.5 million Americans suffer from psoriasis, a lifelong disorder
characterized by inflammation of skin and, often, the joints.
Stelara, Remicade, and Enbrel are all biologics -- drugs made of genetically
engineered proteins -- that are generally
used to treat patients who aren't responding to traditional therapies such as
light therapy and methotrexate.
Remicade and Enbrel both block tumor necrosis factor-alpha (TNF-alpha), a
chemical produced by immune cells that fuels inflammation, much like gas on a
fire. Stelara targets two proteins, interleukin 12 and interleukin 23, that
also drive the inflammatory process.
The new findings show that if Enbrel stops working, "there are other
effective options," says Alan Menter, MD, chair of the psoriasis research unit
at Baylor Research Institute in Dallas.
Menter was an investigator in the Stelara study, a follow-up analysis of a
larger trial of more than 900 patients that showed Stelara was more
effective than Enbrel in the treatment of moderate-to-severe plaque
The new analysis focused on 50 patients who continued to have
moderate-to-severe psoriasis after 12 weeks of Enbrel therapy. Compared with
people who were helped by Enbrel, they tended to be heavier, male, and have
more severe psoriasis.
All were given Stelara injections four weeks and eight weeks later.
Three months later, 40% had, at most, minimal signs of their psoriasis; 70%
had mild disease at most.
The second study involved 217 psoriasis patients who had significant disease
despite ongoing treatment with Enbrel. All were switched to Remicade
"While both drugs block TNF-alpha, they do so in slightly different ways.
There are subtle difference that made us think that Remicade may work more
effectively," says Robert Kalb, MD, a clinical professor of dermatology at the
State University of New York, Buffalo, who was involved in the trial.
By 10 weeks later, two-thirds had, at most, minimal disease.
So if you fail Enbrel, how do you decide whether to try Remicade or
There has been no head-to head comparison, but generally Stelara is reserved
for people with more severe disease, Menter notes.
"Once on it, the vast majority of patients maintain improvement over the
course of the next few years," he adds.